Home > Drug Search >
  • Targets: Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
  •   > 
Drug Filter
Status:
Approved (1) Phase Ⅲ (1) Phase Ⅱ (5) Phase Ⅰ (3)
Clinical Stage:
Pending (1) Active (6) Discontinued (3)
Company:
Japan Tobacco (1) Merck Serono (1) Pfizer (1) Sanofi (1) Wakunaga (1) Unknown (1) Neugen (1) Komipharm (1) GliaCure (1) Reata (1) Canopus (1) Cornerstone Pharmaceuticals (1) PreScience Labs (1) Johns Hopkins University (1) Tufts University (1) Valens (2) Mallinckrodt Pharmaceuticals (1) Abbvie (1)
Indication:
Alzheimer's disease (AD) (1) Amyotrophic lateral sclerosis (ALS) (1) Breast cancer (1) Friedreich's ataxia (1) Hepatocellular carcinoma (HCC) (1) Lung cancer (2) Myelodysplastic syndrome (MDS) (1) Non-Hodgkin’s lymphoma (NHL) (1) Ovarian cancer (1) Pancreatic cancer (2) Prostate cancer (1) Skin infectious (1) Small cell lung cancer (SCLC) (1) Type 2 diabetes (1) Reperfusion injury (1) Skin ulcer (1) Chemotherapy-radiotherapy induced mucositis (1) Ischemic stroke (1) Traumatic brain injury (1) Burns (1) Ocular pain (1) Myocardia ischemia (1) Congenital lactic acidosis (1) Ocular inflammation (1)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top